NeuroPace preliminary Q4 rev $17.5-18.0M (+37-41% YoY); NAUTILUS trial completed early

NeuroPace Inc

Preliminary Q4 2023 revenue $17.5-18.0M, up 37-41% YoY; full year 2023 revenue $64.9-65.4M, up 43-44% YoY, well above initial guidance of $50-52M.
Cash and short-term investments $66.5M as of Dec 31, 2023, including $7.9M from ATM and portion of data collaboration proceeds.
Completed enrolling and implanting patients required for FDA submission in NAUTILUS pivotal trial for idiopathic generalized epilepsy more than a quarter early.
Initial milestones achieved in first strategic data collaboration with a biotech company; expects up to $3.7M in total proceeds over nine quarters.
Project CARE pilot to expand RNS System access to community setting on track for 1H 2024 launch; centers already implanting patients.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NeuroPace Inc reported preliminary financial results for the fiscal quarter and year ended December 31, 2023.

Period: the fiscal quarter and year ended December 31, 2023
Result: preliminary results

Exact text from the filing

On January 8, 2024, NeuroPace issued a press release announcing its preliminary unaudited revenue and cash balance for the fiscal quarter and year ended December 31, 2023, as well as providing a summary of business updates.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001193125-24-003861

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.